These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 35714883)

  • 21. Effectiveness of mepolizumab in patients with severe eosinophilic asthma: results from real-world clinical practice in Finland.
    Koistinen V; Kauppi P; Idänpään-Heikkilä J; Veijalainen L; Iso-Mustajärvi I; Ylisaukko-Oja T; Mehtälä J; Viinanen A; Kilpeläinen M
    J Asthma; 2022 Dec; 59(12):2375-2385. PubMed ID: 35094632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world outcomes of mepolizumab treatment in severe eosinophilic asthma patients - retrospective cohort study in Slovakia.
    Jesenak M; Vanecek V; Ondrusova M; Urdova V; Dostalova K; Hochmuth L
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2023 Sep; 167(3):272-280. PubMed ID: 37439266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mepolizumab Is an Effective Option in Severe Eosinophilic Asthma Regardless of Baseline Features: Single-Center Real-Life Data.
    Özdel Öztürk B; Yavuz Z; Eraslan D; Mungan D; Demirel YS; Aydın Ö; Sin BA; Bavbek S
    Int Arch Allergy Immunol; 2022; 183(5):526-538. PubMed ID: 34915496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry.
    Thomas D; Harvey ES; McDonald VM; Stevens S; Upham JW; Katelaris CH; Kritikos V; Gillman A; Harrington J; Hew M; Bardin P; Peters M; Reynolds PN; Langton D; Baraket M; Bowden JJ; Bowler S; Chien J; Chung LP; Farah CS; Grainge C; Jenkins C; Katsoulotos GP; Lee J; Radhakrishna N; Reddel HK; Rimmer J; Sivakumaran P; Wark PAB; Gibson PG
    J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2715-2724.e5. PubMed ID: 33545399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results in clinical practice in the treatment of severe eosinophilic asthma with mepolizumab: a real-life study.
    Enríquez-Rodríguez AI; Hermida Valverde T; Romero Álvarez P; López-González FJ; Gullón Blanco JA; Expósito Villegas AR; Escobar Fernández MJ; Beristáin Urquiza AM; Alonso Fernández MÁ; Gutiérrez Rodríguez M; Castaño De Las Pozas G; Jiménez Pérez J; Fernández Mellado R; García Clemente MM; Casan Clara P
    J Asthma; 2022 May; 59(5):1005-1011. PubMed ID: 33653213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Matching-adjusted comparison of oral corticosteroid reduction in asthma: Systematic review of biologics.
    Bourdin A; Husereau D; Molinari N; Golam S; Siddiqui MK; Lindner L; Xu X
    Clin Exp Allergy; 2020 Apr; 50(4):442-452. PubMed ID: 31943429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma.
    d'Ancona G; Kavanagh J; Roxas C; Green L; Fernandes M; Thomson L; Dhariwal J; Nanzer AM; Jackson DJ; Kent BD
    Eur Respir J; 2020 May; 55(5):. PubMed ID: 32060061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Effectiveness of Mepolizumab in Patients with Allergic and Non-Allergic Asthma.
    Silver J; Steffens A; Chastek B; Deb A
    J Asthma Allergy; 2024; 17():261-271. PubMed ID: 38544676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral corticosteroid-sparing effects of mepolizumab in severe eosinophilic asthma: evidence from randomized controlled trials and real-world studies.
    Casale TB; Burnette A; Bourdin A; Howarth P; Hahn B; Stach-Klysh A; Khurana S
    Ther Adv Respir Dis; 2022; 16():17534666221107313. PubMed ID: 35972211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study.
    Domingo Ribas C; Carrillo Díaz T; Blanco Aparicio M; Martínez Moragón E; Banas Conejero D; Sánchez Herrero MG;
    Drugs; 2021 Oct; 81(15):1763-1774. PubMed ID: 34586602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective.
    Xu X; Schaefer C; Szende A; Genofre E; Katial R; Chung Y
    J Manag Care Spec Pharm; 2023 Nov; 29(11):1193-1204. PubMed ID: 37796731
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy of mepolizumab treatment in oral corticosteroid-dependent severe eosinophilic asthma patients with chronic rhinosinusitis with nasal polyps: single center, real life study.
    Yilmaz I; Türk M; Nazik Bahçecioğlu S; Tutar N; Gülmez I
    Turk J Med Sci; 2020 Apr; 50(2):433-441. PubMed ID: 32093447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the General Characteristics of Patients with Severe Asthma Who Switched from Omalizumab to Mepolizumab versus Patients Who Responded to Omalizumab Treatment: A Real-Life Study.
    Cakmak ME; Öztop N; Yeğit OO
    Int Arch Allergy Immunol; 2024; 185(2):158-166. PubMed ID: 37992693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.
    Lugogo N; Domingo C; Chanez P; Leigh R; Gilson MJ; Price RG; Yancey SW; Ortega HG
    Clin Ther; 2016 Sep; 38(9):2058-2070.e1. PubMed ID: 27553751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype.
    Basu A; Dalal A; Canonica GW; Forshag M; Yancey SW; Nagar S; Bell CF
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):121-131. PubMed ID: 28277854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma.
    Yancey SW; Ortega HG; Keene ON; Mayer B; Gunsoy NB; Brightling CE; Bleecker ER; Haldar P; Pavord ID
    J Allergy Clin Immunol; 2017 Apr; 139(4):1167-1175.e2. PubMed ID: 27726946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study).
    Martínez-Moragón E; García-Moguel I; Nuevo J; Resler G;
    BMC Pulm Med; 2021 Dec; 21(1):417. PubMed ID: 34922515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term Real-World Outcomes of Mepolizumab and Benralizumab Among Biologic-Naive Patients With Severe Eosinophilic Asthma: Experience of 3 Years' Therapy.
    Fyles F; Nuttall A; Joplin H; Burhan H
    J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2715-2723. PubMed ID: 37245734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of Mepolizumab in Patients with Severe Eosinophilic Asthma with/without Nasal Polyposis: A Real-Life Study.
    Bravo-Gutiérrez FJ; Miralles-López JC; Valverde-Molina J; Alemany Francés ML; Andújar-Espinosa R; Castilla-Martínez M; Avilés-Inglés MJ; Mora-González A; Pajarón-Fernández MJ; Cabrejos-Perotti S; Meseguer-Arce J; Flores Martín I; Pérez-Fernández V;
    Int Arch Allergy Immunol; 2024; 185(3):253-259. PubMed ID: 38035559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study.
    Pavord I; Gardiner F; Heaney LG; Domingo C; Price RG; Pullan A; Oppenheimer J; Brusselle G; Nagase H; Chupp G; Pizzichini E; Bañas-Conejero D; Howarth P
    Front Immunol; 2023; 14():1150162. PubMed ID: 37122713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.